TC BioPharm shares are trading higher after the company announced an AI partnership with Carnegie Mellon University for donor screening.
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm's shares declined following the announcement of a partnership with Carnegie Mellon University to use AI for donor screening.
October 03, 2024 | 7:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TC BioPharm's stock is trading lower after announcing a partnership with Carnegie Mellon University to implement AI in donor screening processes.
The announcement of the AI partnership with Carnegie Mellon University seems to have been perceived negatively by investors, leading to a decline in TCBP's stock price. This could be due to concerns about the costs or risks associated with implementing new AI technologies.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100